DGAP-News: Cytos Biotechnology Ltd (SIX:CYTN) today presents additional results from its Phase 2a study of CYT003 for the treatment of allergic asthma
EQS Group-News: Cytos Biotechnology AG / Key word(s): Research Update Cytos Biotechnology Ltd (SIX:CYTN) today presents additional results from its Phase 2a study of CYT003 for the treatment of allergic asthma 09.09.2013 / 07:00 229498 09.09.2013 ...